NCT00496431View on ClinicalTrials.gov

phII Study of an HDAC Inhibitor in Very High-risk Relapsed/Refractory Hodgkin's Lymphoma Patients

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions
Hodgkin's Lymphoma
Interventions
DRUG

histone deacetylase inhibitor (ITF2357)

50 mg b.i.d. (or every 8 hours or every 6 hours), every day

Trial Locations (1)

20133

Istituto Nazionale per lo studio e la cura dei Tumori, Milan

Sponsors

Lead Sponsor

Italfarmaco
All Listed Sponsors
lead

Italfarmaco

INDUSTRY

NCT00496431 - phII Study of an HDAC Inhibitor in Very High-risk Relapsed/Refractory Hodgkin's Lymphoma Patients | Biotech Hunter | Biotech Hunter